EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics

Da Li, Jun Yan, Kang Li, Qingcheng Yang, Liping Bian, Bencheng Lin, Xiaohua Liu, Zhuge Xi

PeerJ · 2023

DOI: 10.7717/peerj.16426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Da Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Institute of Environmental and Operational Medicine, Tianjin, China. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, to screen for candidate markers of temozolomide (TMZ) resistance in glioblastoma, we artificially established TMZ drug-resistant glioblastoma (GBM) cell lines, U251-TMZ and U87-TMZ. In the U251-TMZ and U87-TMZ cell lines, we screened and analyzed differentially expressed proteins using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) differential proteomics. Compared with the U251 and U87 control cell lines, 95 differential proteins were screened in the U251-TMZ and U87-TMZ cell lines, of which 28 proteins were upregulated and 67 proteins were down-regulated. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of the co-upregulated proteins showed that most of the differentially expressed proteins were located in the cytoplasm and were significantly upregulated in the biological processes related to vesicular transport in the intimal system and inflammatory response mediated by myeloid leukocytes. Seven candidates were identified as potential GBM markers of TMZ resistance. Combined with existing research findings, our study supports that UAP1L1 and BCKDK are promising potential markers of TMZ resistance in GBM. This is important for further understanding the molecular mechanisms that drive the development and enhancement of TMZ resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsGliomaHumansDacarbazineAntineoplastic Agents, AlkylatingChromatography, LiquidProteomicsDrug Resistance, NeoplasmCell Line, TumorTandem Mass SpectrometryTemozolomide

Stichwörter der Autor:innen

Glioma drug resistanceProteomicsTMZUltra-performance liquid chromatography-mass spectrometry

Substanzen

DacarbazineAntineoplastic Agents, AlkylatingTemozolomide

Autor:innen und Institutionen

  • Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.

Zitieren

APA

Li, D., Yan, J., Li, K., Yang, Q., Bian, L., Lin, B., Liu, X., & Xi, Z. (2023). Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics. PeerJ. https://doi.org/10.7717/peerj.16426

Vancouver

Li D, Yan J, Li K, Yang Q, Bian L, Lin B, et al. Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics. PeerJ. 2023. doi:10.7717/peerj.16426

BibTeX
@article{Li2023,
  author = {Li, Da and Yan, Jun and Li, Kang and Yang, Qingcheng and Bian, Liping and Lin, Bencheng and Liu, Xiaohua and Xi, Zhuge},
  title = {Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.16426}
}
Kostenlos starten →